Matches in Ubergraph for { <https://frink.apps.renci.org/.well-known/genid/B8b82f95b0b8d7b8e1640efc682a30e8c> ?p ?o ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- B8b82f95b0b8d7b8e1640efc682a30e8c NCIT_P378 "NCI" @default.
- B8b82f95b0b8d7b8e1640efc682a30e8c type Axiom @default.
- B8b82f95b0b8d7b8e1640efc682a30e8c annotatedProperty IAO_0000115 @default.
- B8b82f95b0b8d7b8e1640efc682a30e8c annotatedSource NCIT_C181776 @default.
- B8b82f95b0b8d7b8e1640efc682a30e8c annotatedTarget "An orally bioavailable inhibitor of Bruton's tyrosine kinase (BTK), with potential antineoplastic activity. Upon oral administration, zebutinib targets, binds to and inhibits the activity of BTK and prevents the activation of the B-cell antigen receptor (BCR) signaling pathway. This prevents both B-cell activation and BTK-mediated activation of downstream survival pathways. This leads to an inhibition of the growth of malignant B-cells that overexpress BTK. BTK, a member of the src-related BTK/Tec family of cytoplasmic tyrosine kinases, is overexpressed in B-cell malignancies; it plays an important role in B-lymphocyte development, activation, signaling, proliferation and survival." @default.